Condition
Angiotensin II Type 1 Receptor Blockers
Total Trials
4
Recruiting
1
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 90/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (3)
P 4 (1)
Trial Status
Unknown1
Recruiting1
Completed1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05465031Phase 4Recruiting
Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)
NCT00565396Not ApplicableUnknown
Effectiveness Study on Fosinopril and/or Losartan in Patients With Chronic Kidney Disease Stage 3
NCT00561704Not ApplicableCompleted
Adiponectin in Obese Women With T2DN and Effects by RAS Blocker
NCT00338091Not ApplicableTerminated
Long-Term Renoprotection of Optimal Antiproteinuric Doses of Benazepril and Losartan in Chronic Renal Insufficiency
Showing all 4 trials